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ABSTRACT
Resveratrol, a naturally occurring polyphenol in red grapes and berries, can act as a phytoestrogen. It has been shown to improve
both systemic and cerebral circulatory functions, possibly through activation of endothelial estrogen receptors. in vitro and in vivo
studies in rodent models also indicate a bone-protective role for resveratrol, particularly in ovariectomized rat models that mimic
postmenopausal osteoporosis caused by estrogen deficiency. Hypothesizing a circulatory benefit of resveratrol in bone tissue, we
investigated whether resveratrol supplementation could improve bone health in postmenopausal women. The Resveratrol for
Healthy Aging in Women (RESHAW) trial was a 24-month randomized, double-blind, placebo-controlled, two-period crossover inter-
vention conducted to evaluate the effects of resveratrol (75 mg twice daily) on cognition, cerebrovascular function, bone health, car-
diometabolic markers, and well-being in postmenopausal women. After 12 months of supplementation with resveratrol versus
placebo, there were positive effects on bone density in the lumbar spine (+0.016  0.003 g/cm2) and neck of femur
(+0.005  0.002 g/cm2), which were accompanied by a 7.24% reduction in C-terminal telopeptide type-1 collagen levels, a bone
resorption marker, compared with placebo. The increase in bone mineral density in the femoral neck resulted in an improvement
in T-score (+0.070  0.018) and a reduction in the 10-year probability of major and hip fracture risk. The magnitude of improvement
was higher in womenwith poor bone health biomarker status. Importantly, the improvement in femoral neck T-score with resveratrol
correlated with improvement in perfusion. Our subanalysis also revealed that the bone-protective benefit of resveratrol was greater
in participants who supplemented with vitamin D plus calcium. Regular supplementation with 75 mg of resveratrol twice daily has
the potential to slow bone loss in the lumbar spine and femoral neck, common fracture sites in postmenopausal women without
overt osteoporosis. © 2020 American Society for Bone and Mineral Research. © 2020 The Authors. Journal of Bone and Mineral
Research published by American Society for Bone and Mineral Research..
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Introduction
Osteoporosis is a silent disease characterized by progressivedeterioration of bone tissue, gradually compromising bone
strength. Unsuspecting individuals are often confronted with a
detrimental hip fracture resulting from a fall or suffer from
long-standing back pain caused by crushed vertebrae. The two
most common forms of primary osteoporosis in the elderly are
postmenopausal osteoporosis (type 1) and senile osteoporosis
(type 2). The powerful ability of estrogen to suppress osteoclast
activity in the resorption phase and enhance its apoptosis is lost
with estrogen depletion at menopause. Trabecular bone is espe-
cially affected in postmenopausal osteoporosis where women
lose an impressive 12% of bone mass within 5 to 7 years, an
equivalent of one T-score measured by dual-energy X-ray
absorptiometry (DXA).(1,2) The greater loss of trabecular than cor-
tical bone predisposes individuals to low-trauma vertebral frac-
tures that remain undetected.(3) Senile osteoporosis is caused
by age-related bone loss associated with decreased proliferation
of osteogenic stem cells, which slows bone formation.(4,5) Elderly
postmenopausal women are likely to have both etiologies.
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Increasingly, evidence suggests that intraosseous blood
vessels serve as a source for mesenchymal stem cells to
induce their differentiation into osteoblasts for new bone for-
mation.(6) Aging decreases the quality of the blood supply to
body tissues, and it can further compromise bone perfusion
in the presence of chronic diseases. Hypoxia upregulates
osteoclast activities and inhibits osteoblast as shown in
in vitro studies,(7,8) which may account for the consistent epi-
demiological link between osteoporosis and ischemic vascu-
lar diseases.(9) Addressing microvascular dysfunction may
represent an additional pathway to counteract future
osteoporosis.
Phytoestrogens such as soy isoflavones and resveratrol
have structural similarity to estrogen and can bind to estro-
gen receptors to exert a multitude of benefits for which
estrogen is responsible, and they have attracted interest
as potential bone health therapies in estrogen-deficient
postmenopausal women. A 24-month randomized con-
trolled trial in a large cohort of osteopenic postmenopausal
women provided strong evidence of a clinical indication for
soy isoflavones on bone health. There was a progressive
increase in bone mineral density (BMD) of the femoral neck
rising from 3.5% at 12 months up to 9.3% by the end of the
trial with a daily supplement of 56 mg genistein, 500 mg
calcium carbonate, and 400 IU vitamin D compared with
placebo.(10) The BMD changes were attributed to the
increase in osteoprotegerin, a soluble decoy receptor for
receptor activator of NF-κB ligand (RANKL) that inhibits dif-
ferentiation and function of osteoclasts.(11) Soy isoflavones
have been shown to improve endothelial function; how-
ever, no studies have linked the bone benefits with
improved vascular function.(12)
Resveratrol is a stilbene found on skins of red grapes and
berries and has been shown in animal models to promote
osteoblast-mediated bone formation and inhibit
osteoclast-stimulated bone resorption via similar mecha-
nisms to genistein.(13) To date, only three clinical studies
have evaluated the effects of resveratrol on BMD, but their
results were lackluster.(14–16) None of the studies supple-
mented participants for more than 6 months or were under-
taken in postmenopausal women to see whether estrogenic
effects of resveratrol can counteract postmenopausal osteo-
porosis. The cardiovascular benefits of resveratrol, on the
other hand, are well established.(17) In an acute dose–
response study in adults with type 2 diabetes, we found that
75 mg resveratrol was equally or more efficacious than
150 mg and 300 mg doses for enhancing cerebral vasodilata-
tion and improving sustained attention.(18,19) In a follow-up
study, we have reported improvements of cerebrovascular
function in postmenopausal women after 14 weeks of resver-
atrol supplementation.(20) The benefits of resveratrol for cere-
brovascular function might also be partially mediated by the
activation of estrogen receptors on endothelial cells to facili-
tate vasodilatation.(21) It is plausible that the ability of resver-
atrol to enhance microvascular perfusion may also benefit
bone health, especially in postmenopausal women. In the pre-
sent study, we investigated whether resveratrol has beneficial
effects on BMD in postmenopausal women and, if so, whether
there is any potential interaction with vitamin D and/or cal-
cium supplements as older adults often consume them. In
addition, we aimed to elucidate whether any treatment
changes in our measured bone parameters correlate with
resveratrol-induced improvements in vascular function.
Materials and Methods
Study design
The Resveratrol for Healthy Aging in Women (RESHAW) trial is a
24-month randomized, double-blind, placebo-controlled, two-
period crossover intervention conducted to evaluate the effects
of resveratrol supplementation (75 mg twice daily) on cognitive
performance, cerebrovascular function, bone health, cardiome-
tabolic markers, and well-being in postmenopausal women.
The outcomes for cognitive performance, cerebrovascular func-
tion, and cardiometabolic markers are published elsewhere.(22)
This article now reports outcomes for bone health and bio-
markers of bone metabolism.
RESHAW was conducted at the Clinical Nutrition Research
Centre of the University of Newcastle, Australia, in accordance
with the Declaration of Helsinki and the Principles of Good Clin-
ical Practice as outlined by the International Conference on Har-
monization. Written informed consent was obtained before any
assessment. The protocol was approved by the University of
Newcastle’s Human Research Ethics Committee (H-2016-0091)
and registered with the Australia and New Zealand Clinical Trials
Registry (ACTRN12616000679482p).
Participants
Between November 2016 and June 2017, community-dwelling
women from the Hunter region of New South Wales in
Australia were recruited through approved newspaper and
radio campaigns and from a database of previous participa-
tion in our Centre’s trials and the Hunter Medical Research Vol-
unteers Registry. To be included in the study, participants
were aged 45 to 85 years, more than 12 months of cessation
of menses, and not taking hormone replacement therapy.
We excluded participants who took insulin or warfarin or had
a history of breast or cervical cancer, major heart, kidney or
liver disease, a neurological disorder, clinical depression, or
suspected dementia.
Intervention and randomization
Resveratrol (Veri-te resveratrol) capsules (containing 75 mg of
>98% of trans-resveratrol) and placebo capsules (comprising sev-
eral inert excipients) of identical shape and color were supplied
by Evolva SA (Reinach, Switzerland). Capsules were dispensed in
containers identifiable only by code numbers. An independent
investigator who was not involved in recruitment or data collec-
tion held the code and allocated volunteers to resveratrol or pla-
cebo capsules using Altman’s randomization by minimization
procedure,(23) balancing the treatment groups based on age,
menopausal years, and clinic blood pressure at the screening
visit. All other investigators and participants were blinded to the
supplement allocation throughout data collection and analysis.
Participants were instructed to take two capsules of their allo-
cated treatment each day (one in themorning and one in the eve-
ning) for 12 months, after which they crossed over to the alternate
treatment for a further 12 months. Participants were also encour-
aged to maintain their habitual diet, including other dietary sup-
plements, and physical activity levels throughout the 2-year study.
Bone density and bone metabolism assessments
We assessed the participants’ bone density and bloodmarkers of
bone metabolism at baseline and the end of each treatment
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phase. Participants attended the clinic in the mornings after an
overnight fasting of more than 8 hours and voided their blad-
ders before changing into a disposable paper gown. Using a
Lunar Prodigy densitometer, areal BMD was measured by DXA
in the lumbar spine (L1 to L4), left and right hip (total hip and neck
of femur) and the whole body in an anterior–posterior plane
(GE Healthcare Lunar, Madison, WI, USA). Baseline and follow-
up scans were obtained with the same instrument. On the dates
of data acquisition, at least 10 phantom scans were performed in
accordance with the manufacturer’s instructions to ensure that
the densitometer stability and BMD measurement precision
remained within 0.4% from the reference value. Between
November 2017 and June 2019, the instrument precision was
0.267%. Licensed technicians (ie, authors RHXW and JJTZ)
obtained all scans on the participants. The precision of reposi-
tioning at our site expressed as the root mean square of the per-
cent coefficient of variation (RMS-% CV) was 0.52% for the spine,
0.39% for femur neck, 0.51% for total hip, and 0.26% for the
whole body. The integrated software (GE Healthcare Encore soft-
ware v16) was used to generate the BMD, T-scores, and Z-scores
for the lumbar spine, hip, and whole body. Region-of-interest in
the spine, hips, or whole body scans were manually adjusted
and excluded if necessary on scans showing metal artifacts or
breast implants or severe scoliosis and/or severe degenerative
disc disease. In participants with a hip replacement, the contra-
lateral hip was used.
The BMD values of the dual neck of femur obtained with the
DXA and the participants’ relevant medical history were entered
into the Fracture Risk Assessment Tool (FRAX) calculator for
Australia region to obtain participants’ T-scores at the hip and
the 10-year probability of sustaining a major osteoporotic frac-
ture and hip fracture (https://www.sheffield.ac.uk/FRAX/tool.
aspx?country=31).
Venous blood samples were obtained immediately after their
DXA scans. Blood samples were centrifuged at 4000g for
10 minutes at 4C and the plasma was divided into aliquots
and stored at −80C within 2 hours of collection. Pathology
New South Wales, a commercial pathology laboratory in the
Hunter region of New South Wales, assessed the samples for
plasma levels of osteocalcin and C-terminal telopeptide type-1
collagen (CTX), markers of bone formation and bone resorption,
respectively.
Cerebral vasodilator responsiveness to a hypercapnic
challenge
A detailed description of the methodology for cerebrovascular
responsiveness (CVR) to hypercapnia assessment can be found
in our previous publications.(20,22) Briefly, participants fasted at
least 2 hours before breathing in a carbogen gas mix (95%
O2/5% CO2) for 3 minutes. Transcranial Doppler ultrasound was
used to detect changes in mean blood flow velocity of the mid-
dle cerebral arteries. The percent change from mean blood flow
velocity at rest to the peak velocity denotes the CVR, which is an
indirect measure of maximum global cerebral perfusion capacity
in response to the metabolic demand. Higher values of CVR
reflect superior cerebrovasodilator capacity. This marker is used
as a surrogate measure of overall vascular function.
Sample size and statistical analysis
The sample size for the RESHAW trial was calculated based on
the primary outcome, which was the mean within-individual
difference in overall cognitive performance between resveratrol
and placebo treatment phases. For 90% power to detect a statis-
tically significant (p < 0.05) medium effect size (Cohen’s d = 0.5)
improvement in the primary outcome, 87 completers were
required in the crossover comparison. To allow for 45% attrition
due to a long-term study, we aimed to recruit 170 women. This
article will also report a parallel comparison analysis performed
at the end of the first 12-month phase of the crossover to com-
pare mean treatment changes (post-pre supplementation)
between the placebo and resveratrol arms. For 80% power to
detect a statistically significant (p < 0.05) medium effect size in
the parallel comparison, 64 people per arm were required.
For the parallel analysis, an independent t test was used to
compare the change from baseline between the placebo group
and the resveratrol group. Within-individual treatment effects
at the end of each supplementation period were compared
using repeated measures ANOVA (analysis of variance). The
Benjamini-Hochberg procedure(24) was used to correct p values
for all variables in this analysis as they were secondary outcomes
in the RESHAW trial to minimize type 1 errors; the false discovery
rate was set at 0.15 unless otherwise stated.
We undertook an exploratory subgroup analysis to identify
potential interactions with the resveratrol treatment according
to participants’ baseline bone density T-score bone health classi-
fication in the hip and regular use of vitamin D and/or calcium
supplements. Pearson’s correlation was used to test for a rela-
tionship between treatment change in CVR and changes in bone
parameters (ie, BMD and T-scores). All tests in the exploratory
analysis were two-tailed and p < 0.05 was considered significant.
All analyses were performed with SPSS version 25.0 (SPSS by
IBM Inc., Chicago, IL, USA). Data are presented as mean  SEM
(standard error of the mean).
Results
Participant characteristics
The flow of participants is depicted in Fig. 1. At the end of the first
12-month intervention phase, 66 women in the placebo group
and 63 in the resveratrol group returned to the clinic for reassess-
ments of outcome measures, and 125 women completed the
2-year crossover trial by June 2019. Details of the adverse events
have been reported.(22) Briefly, of the 12 adverse events
reported, 4 occurred in the resveratrol group but were not neces-
sarily attributed to supplementation (viz., itching, menses, pro-
lapsed bladder, and prescheduled eye operation). Based on
capsule counts, overall compliance was 95% and 94% for pla-
cebo and resveratrol groups, respectively, over the first
12 months of the intervention. For the crossover analysis, the
average compliance was 96% for both groups.
In the crossover analysis, we excluded data from 7 participants
because they had sustained a fracture (n = 1), had joint replace-
ment surgery (n = 4), commenced denosumab (Prolia) therapy
(n = 1), or ceased risedronic acid (Acetonel) therapy (n = 1) after
study enrollment. We also excluded lumbar spine data from
2 participants because of severe spinal stenosis or awaiting sur-
gery upon completion of the 2-year study.
The women in the study were marginally overweight but nor-
motensive. Based on their femoral neck T-scores at enrollment,
our cohort was mildly osteopenic (defined as T-score between
−1.0 and − 2.5). Specifically, 50 women had normal bone den-
sity, 72 women had osteopenia, and 6 women had osteoporosis
in the hips (T-score < −2.5). One participant had a double-hip
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joint replacement; her lumbar spine T-score was used instead for
this classification. Baseline characteristics did not differ signifi-
cantly between those allocated to placebo and resveratrol at
enrollment (Table 1).
Baseline profiles of the bone health parameters of partici-
pants who did not take any vitamin D or calcium supplements
and those who took vitamin D only, calcium only, or both are
presented in Supplemental Table S1. There were no significant
differences in age between participants who took vitamin D
and/or calcium supplements and those who took neither sup-
plement. At baseline, participants who were regularly
consuming vitamin D only had greater BMD in the lumbar
spine compared with those who took neither supplement. Par-
ticipants who consumed both vitamin D and calcium had sig-
nificantly lower BMD and T-score in the neck of femur
(−8.5%) compared with those who took neither supplement
(Supplemental Table S1). Four participants were prescribed
Prolia and remained on treatment throughout the study. In
addition to their bone-active medication, one participant regu-
larly consumed vitamin D only, one participant consumed cal-
cium only, another participant consumed both supplements,
and one participant took neither.
Fig 1. Consort diagram. Flow of participants from initial contact to final follow-up and available data for parallel analysis and crossover comparison.
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Cohort data (parallel analysis)
Table 2 presents bone health status after 12 months of placebo
or resveratrol supplementation. There was no difference in
whole body BMD after resveratrol supplementation compared
with placebo. However, relative to placebo, BMD increased in
the lumbar spine by a modest 1.3% (q* = 0.049), thus improving
themean T-score by 1.5% (q* = 0.079) (Fig. 2). Likewise, BMD and
corresponding T-scores in the neck of femur and total hip were
also increased by resveratrol relative to placebo, which in turn
significantly attenuated the 10-year probability of sustaining a
Table 1. Demographic and Bone Health Status at Baseline of Participants Who Completed the First Intervention Phase of the Study
Characteristics Placebo (n = 65) Resveratrol (n = 63) p Value
Age (years) 65.8  1.3 64.3  1.3 0.772
Menopausal years 15.6  1.1 15.5  1.2 0.947
Body mass index (kg/m2) 25.7  0.5 25.6  0.5 0.867
Systolic BP (mmHg) 125  2 124  2 0.743
Diastolic BP (mmHg) 69  1 68  1 0.529
Pulse rate (bpm) 61  1 62  1 0.740
Lumbar spine
BMD (g/cm2) 1.085  0.019 1.088  0.021 0.916
T-score −1.08  0.11 −1.13  0.11 0.749
Z-score 0.59  0.17 0.62  0.12 0.801
Neck of femur
BMD (g/cm2) 0.886  0.015 0.881  0.013 0.836
T-score −1.09  0.11 −1.13  0.10 0.764
Z-score 0.51  0.12 0.53  0.10 0.919
Total hip
BMD (g/cm2) 0.916  0.016 0.919  0.011 0.785
T-score −0.69  0.12 −0.75  0.12 0.714
Z-score 0.44  0.13 0.43  0.09 0.923
10-year major fracture risk (%) 4.7  0.5 5.5  0.5 0.263
10-year hip fracture risk (%) 1.1  0.3 1.6  0.3 0.272
Total body BMD (g/cm2) 1.122  0.014 1.129  0.015 0.768
Osteocalcin (μg/L) 20.5  0.7 20.8  0.8 0.764
CTX (ng/L) 423.3  24.2 467.4  22.4 0.184
Never took supplements (n) 48 49 —
Vitamin D only (n) 7 9 —
Calcium only (n) 2 0 —
Vitamin D and calcium (n) 8 5 —
BP = blood pressure; bpm = beats per minute; BMD = bone mineral density; CTX = C-terminal telopeptide type-1 collagen.
Table 2. Outcomes of Bone Health After 12 Months of Placebo or Resveratrol Supplementation in the Parallel Comparison
Placebo Resveratrol Δresveratrol-Δplacebo [95% CI] p Value (absolute) q* (FDR)
Lumbar spine n = 65 n = 61 q < 0.15
BMD (g/cm2) 1.073  0.018 1.090  0.02 0.014  0.005 [0.004, 0.024] 0.007 0.049
T-score −0.841  0.159 −0.702  0.165 0.116  0.048 [0.042, 0.227] 0.017 0.079
Z-score 0.592  0.164 0.723  0.170 0.074  0.050 [0.025, 0.203] 0.140 0.178
Femur and total hip n = 65 n = 63
Neck BMD (g/cm2) 0.877  0.015 0.878  0.014 0.009  0.005 [−0.001, 0.019] 0.065 0.137
Neck T-score −1.161  0.107 −1.148  0.098 0.075  0.038 [−0.003, 0.142] 0.047 0.121
Neck Z-score 0.506  0.117 0.917  0.016 0.079  0.043 [−0.008, 0.158] 0.068 0.136
Total hip (g/cm2) 0.917  0.016 0.913  0.016 0.006  0.004 [−0.006, 0.012] 0.200 0.137
Total hip T-score −0.721  0.131 −0.755  0.128 0.028  0.037 [−0.051, 0.093] 0.441 0.475
Total hip Z-score 0.445  0.136 0.460  0.132 0.037  0.038 [−0.043, 0.107] 0.322 0.376
Major fracture risk (%) 5.62  0.61 5.17  0.45 −0.376  0.192 [−0.755, 0.004] 0.052 0.121
Hip fracture risk (%) 1.56  0.39 1.51  0.28 −0.432  0.208 [−0.844, −0.020] 0.040 0.121
Whole body n = 65 n = 63
Total BMD (g/cm2) 1.117  0.014 1.124  0.015 0.007  0.003 [−0.006, 0.007] 0.871 0.871
Osteocalcin (μg/L) 19.5  0.9 19.3  0.8 −1.091  0.951 [−2.972, 0.790] 0.253 0.656
CTX (ng/L) 404.5  23.5 427.5  19.2 −31.69  19.22 [−69.81, 6.43] 0.098 0.137
CI = confidence interval; FDR = false discovery rate; BMD = bone mineral density; CTX = C-terminal telopeptide type-1 collagen.
Q* (FDR) is the level of significance after applying false discovery rate of 0.15 to the cohort’s data.
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major osteoporotic fracture or hip fracture. There was a trend
toward a reduction of CTX after 12 months of resveratrol supple-
mentation (Δplacebo: −7.35  13.72 ng/L versus Δresveratrol:
−39.04  13.46 ng/L). Plasma osteocalcin levels were unaffected
by supplementation.
Cohort data (crossover analysis)
As shown in Table 3, our crossover analysis confirms the
results of the 12-month parallel analysis. Compared with the
placebo treatment, the improvement in BMD at the lumbar
spine and neck of femur and femoral neck T-score remained
significantly higher after resveratrol treatment. In addition,
CTX was now significantly lower than placebo. However, major
osteoporotic fracture and hip fracture risks were not signifi-
cantly different between the treatments. Furthermore, the
improvement in total hip BMD was no longer significant
because it exceeded the precision error threshold. Whole
body BMD and osteocalcin levels remained unaffected with
resveratrol supplementation.
Fig 2. Treatment changes from baseline values of (A) lumbar spine bone mineral density (BMD), (B) lumbar spine T-score, and (C) femoral neck T-score.
* indicates q* < 0.15.
Table 3. Crossover Comparisons of Bone Mineral Density of Lumbar Spine, Femur, Total Hip, and Whole Body After Placebo and Resver-
atrol Supplementation
Baseline Placebo Resveratrol Resveratrol-placebo [95% CI]
p Value
(absolute) q* (FDR)
Lumbar spine (n = 115) q < 0.15
BMD (g/cm2) 1.089  0.013 1.069  0.015 1.085  0.014 0.016  0.003 [0.009, 0.022] <0.001 <0.001
T-score −0.75  0.11 −1.02  0.11 −0.87  0.11 0.151  0.028 [0.096, 0.207] <0.001 <0.001
Z-score 0.62  0.11 0.44  0.12 0.58  0.11 0.144  0.026 [0.092, 0.196] <0.001 <0.001
Femur and total hip
(n = 117)
Neck BMD (g/cm2) 0.883  0.010 0.870  0.011 0.875  0.011 0.005  0.002 [0.000, 0.010] 0.035 0.058
Neck T-score −1.11  0.07 −1.20  0.075 −1.17  0.075 0.035  0.018 [6.968 x 10−5, 0.069] 0.050 0.068
Neck Z-score 0.52  0.08 0.49  0.08 0.53  0.09 0.047  0.019 [0.009, 0.085] 0.016 0.034
Total hip (g/cm2) 0.917  0.011 0.908  0.012 0.911  0.012 0.004  0.002 [0.000, 0.007] 0.029 0.054
Total hip T-score −0.72  0.09 −0.80  0.10 −0.77  0.10 0.027  0.014 [1.907 x 10−6, 0.054] 0.050 0.068
Total hip Z-score 0.43  0.09 0.41  0.10 0.45  0.10 0.036  0.013 [0.009, 0.062] 0.009 0.023
Major fracture risk (%) 5.1  0.4 5.8  0.4 5.7  0.4 −0.047  0.172 [0.388, 0.295] 0.787 0.787





1.123  0.010 1.114  0.10 1.115  0.010 0.001  0.002 [−0.003, 0.005] 0.654 0.700
Osteocalcin (μg/L) 20.3  0.6 19.4  0.7 19.1  0.6 −0.26  0.49 [−1.25, 0.72] 0.598 0.690
CTX (ng/L) 438.8  17.7 439.7  17.4 408.0  15.8 −31.76  11.15 [−53.92, −9.61] 0.005 0.015
CI = confidence interval; FDR = false discovery rate; BMD = bone mineral density; CTX = C-terminal telopeptide type-1 collagen.
Q* (FDR) means the adjusted level of significance after applying false discovery rate of 0.15.
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We sought to see whether the magnitude of change in bone
metabolism with resveratrol was influenced by baseline bone
biomarkers. Indeed, there was a negative correlation between
the treatment difference in CTX and baseline CTX levels
(r = −0.208, p = 0.047). A stronger correlation was observed
between the treatment difference in osteocalcin and baseline
osteocalcin levels (r = −0.347, p < 0.001).
Fig. 3 shows the difference in BMD values of the lumbar
spine, femoral neck, total hip, and whole body measured
between baseline and month-12 values, and month-12 and
month-24 of the two groups at the end of each treatment
phase. Group 1 was randomized to placebo treatment and
group 2 received resveratrol in the first 12-month arm; they
then crossovered to the alternate treatment for another
12 months. In group 1, BMD of the lumbar spine, femoral neck,
and total hip increased at month-24 from their placebo values
(at month-12) after supplementing with resveratrol. In fact, the
increase in BMD of the lumbar spine was higher than the base-
line value. The resveratrol-related BMD increase at the femoral
neck and total hip did not return to their baseline values. In
general, BMD values at the four sites decreased at month-24
after placebo treatment in group 2; however, the decrease in
BMD of the lumbar spine appeared to be attenuated after the
crossover to placebo and remained higher than the baseline
value.
Treatment responsiveness in those supplemented with
vitamin D or calcium or both
In the parallel analysis, the treatment difference frombaseline in the
spine BMD in the resveratrol group was greater in those who took
calcium (+0.068 g/cm2) or both vitamin D and calcium
(+0.036 g/cm2) compared with those who took neither
(+0.002 g/cm2). The increase in spine BMD in those who took cal-
cium only was greater than in those who took vitamin D only. The
treatment difference from baseline in total hip BMD was also
greater in the calcium only (+0.039 g/cm2) and vitamin D only
(−0.020 g/cm2) groups compared with those who took neither
(−0.006 g/cm2) (Supplemental Table S2). The factorial analysis con-
firmed the additive benefits for lumbar spine BMD of taking resver-
atrol together with vitamin D or calcium (Supplemental Table S3).
In the crossover comparison, the benefit of resveratrol over
placebo on lumbar spine BMD was enhanced in those who reg-
ularly supplemented with both vitamin D and calcium
(+0.028 g/cm2) compared with the calcium only (−0.026 g/cm2)
group (Supplemental Table S4). Similarly, the women taking
both vitamin D and calcium had an absolute increase of
0.027 g/cm2 in total hip BMD compared with the none group
(+0.004 g/cm2), which resulted in a 1.3% reduction in hip fracture
risk. Our factorial analysis did not show further additive effects
(Supplemental Table S5).
Fig 3. Change of bone mineral density (BMD) from baseline to month-12 and month-24 in the whole body, lumbar spine, total hip, and femoral neck for
group 1 (placebo then resveratrol) and group 2 (resveratrol then placebo).
Journal of Bone and Mineral Research RESVERATROL IMPROVES POSTMENOPAUSAL BONE HEALTH 2127 n
Correlations between treatment change in CVR and
change in bone health parameters
The treatment increases in femoral neck T-score correlated with
increases in CVR (R = 0.323, p = 0.013). This correlation predomi-
nated in the group taking a vitamin D supplement only
(R = 0.875, p = 0.004) but was still evident in the group taking nei-
ther vitamin D nor calcium (R = 0.297, p = 0.050). Treatment
improvements in CVR did not correlate with all other bone
parameters.
Discussion
RESHAW is the longest clinical trial of resveratrol supplementa-
tion undertaken in postmenopausal women. After 12 months
of supplementation with a low dose of resveratrol (75 mg twice
daily), we found positive effects compared with placebo on bone
density in the lumbar spine and neck of femur, which were
accompanied by a reduction of plasma CTX. The increased
BMD in the femoral neck resulted in improvement of T-score
and reduction in the 10-year probability of major and hip frac-
tures. Importantly, the improvement in femoral neck T-score
with resveratrol correlated with improvement in CVR to a hyper-
capnic challenge, which is a surrogate measure of cerebral vaso-
dilator capacity and a potential general indicator of the ability of
the microvasculature to deliver blood to tissues.
Three randomized controlled trials have been published
reporting effects of resveratrol supplementation on bone health,
but supplementation did not exceed 6 months in any of the
studies. In a recent study, older adults with type 2 diabetes were
supplemented for 6 months with resveratrol at a dose of
500 mg/d, which increased whole body BMD by 0.9% compared
with placebo. However, no increase was observed at the lumbar
spine or hip,(14) which are critical sites advocated by the Interna-
tional Society for Clinical Densitometry (ISCD) for diagnosing
osteoporosis based on the lowest DXA scan T-score of either
the femoral neck or lumbar spine.(25) Similarly, in middle-aged
menwith metabolic syndrome, increases in lumbar spine or total
hip BMD after 16 weeks of resveratrol (500 mg twice daily) were
no different to either placebo or a lower resveratrol dose (75 mg
twice daily). Nonetheless, a 2.6% relative increase in the trabecu-
lar volume density of the lumbar spine was evident at the higher
resveratrol dose, which correlated with a 16% increase in bone
alkaline phosphatase, a marker of bone formation. Treatment
changes in osteocalcin or CTX with resveratrol did not differ from
those of the placebo.(15) One study reported an increase in bone
alkaline phosphatase but not markers of bone resorption in
obese males supplemented for 4 weeks with 500 mg resveratrol
daily.(16)
The results of our study in postmenopausal women are better
than previously published studies of the bone-protective effects
of resveratrol undertaken in other target populations. Even in the
parallel analysis, changes from baseline in BMD of the lumbar
spine and femoral neck, which are the critical regions outlined
by ISCD, as well as the total hip were significantly greater in the
resveratrol arm than the placebo arm. In particular, the attenua-
tion in the decline in femoral neck T-score translates to reduction
in hip fracture risk, which may be of clinical significance for those
postmenopausal women at a lower risk of an osteoporotic frac-
ture, enabling them to optimize their bone health with a dietary
supplement. The within-individual crossover comparisons con-
firmed these increases in BMD, apart from the total hip. Although
we did not assess bone alkaline phosphatase or see an increase
in osteocalcin levels, there was a relative reduction of 7.2% in
the bone resorption marker, CTX, which none of the abovemen-
tioned studies had reported. In fact, participants with higher
baseline CTX levels showed greater reductions of CTX levels with
resveratrol. Likewise, we saw a stronger correlation between
women with lower osteocalcin levels at baseline and the
increase in osteocalcin with resveratrol relative to placebo, sug-
gesting a greater potential for resveratrol to improve bone for-
mation in those individuals at risk of rapid bone loss. It is worth
noting that the effective dose of 75 mg for the bone health ben-
efits observed in this study is 80 times higher than the average
daily dietary intake. Findings from a Spain population where
their main source of resveratrol intake is from drinking wine
showed that the average dietary intake for trans-resveratrol
was 0.933 mg/d;(26) hence, supplementation is necessary.
4.1.1.. Resveratrol versus genistein
Another phytoestrogen, the soy isoflavone genistein, has also
been shown to benefit bone health in postmenopausal women.
A clinical trial in 389 osteopenic postmenopausal women evalu-
ated the effects of 56 mg/d of genistein (plus 400 IU of vitamin
D) and found a remarkable BMD increase in the femoral neck
(+0.023 g/cm2) and lumbar spine (+0.055 g/cm2) relative to pla-
cebo after 12 months of supplementation. BMD continued to
increase in the second year of supplementation.(10) Although
the genistein-induced BMD increase at the two skeletal sites
appeared greater than in our study (femoral neck +0.009 g/cm2;
lumbar spine +0.014 g/cm2), our participants were older
(65 years old versus 54 years old) but had better bone health at
baseline and reported fewer cases and severity of adverse events
relating to resveratrol. As discussed above, individuals with
poorer bone health are likely to show greater improvement with
resveratrol; this may also be the case with genistein. Moreover,
observations from a cross-sectional study suggested benefits of
soy isoflavones might be less pronounced in older compared
with younger postmenopausal women.(27) These factors might
account for the lower absolute BMD increase observed with res-
veratrol compared with genistein.
Resveratrol as a prophylactic in osteoporosis prevention
A longitudinal study of elderly residents living in the city of
Dubbo in regional New South Wales of Australia reported an
annual rate of decline of 0.96  4.08% in BMD of the femoral
neck and − 0.04  3.09% in BMD of the lumbar spine in women
>60 years old.(28) Results from our parallel analysis showed a
1.0% decline in femoral neck BMD in the placebo group, in line
with the population’s annual rate of decline. In the resveratrol
group, the rate of decline in femoral neck BMD from baseline
was 0.34% after 12 months of supplementation, suggesting the
potential to slow the decline through regular resveratrol
supplementation.
In the parallel analysis, the change in lumbar spine BMD from
baseline was −0.55% in the placebo group, which was higher
than the published population average, but there was a
+ 0.46% increase in BMD from baseline in the resveratrol group.
Owing to the positive association between high whole body
BMD and incidence of radiographic osteoarthritis, independent
of joint symptoms, the coexistence of spinal osteoarthritis and
the large variation in spine BMD tends to obscure interpretations
of treatment efficacy.(29) We excluded data of participants with
symptomatic spinal osteoarthritis or scoliosis from the analysis,
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thereby limiting this confounder. In osteoporotic postmeno-
pausal women, anti-fracture therapy with strontium ranelate
(2 g/d) increased lumbar spine BMD by 13.6% over 2 years and
reduced risk of new vertebral fracture by 49% in the first year
of treatment relative to placebo.(30) It is encouraging to see that
the modest increase of 1.5% in spine BMD in our study is not lim-
ited to those with compromised bone health, as there was no dif-
ference in treatment responsiveness between participants with
normal bone density and those with osteopenia/osteoporosis.
The crossover study design allowed us to observe carryover
effects after treatment cessation. Although we did not expect
the resveratrol-related BMD increase to persist after switching
to placebo, the preservation of the BMD increase in the lumbar
spine for 12 months after cessation of resveratrol is promising.
Whether the increase in lumbar spine BMD with resveratrol is
protective against future vertebral fracture in postmenopausal
women with normal bone density is still unknown.
Potential mechanisms of resveratrol for improving bone
health
We believe that resveratrol can act through multiple mecha-
nisms, particularly the estrogenic pathway, to exert positive
effects on bone health in postmenopausal women. For instance,
there was a slowing of BMD loss and deterioration of the trabec-
ular structure of the femoral neck with resveratrol supplementa-
tion in ovariectomized rats.(31) Resveratrol has an estrogen-like
effect on bone by increasing gene expression of osteoprote-
gerin, a protein that inhibits RANKL to counteract osteoclast dif-
ferentiation at the precursor stage and activity at maturity.(31)
Reduction of bone loss in the vertebrae associated with
increased bone formation markers, alkaline phosphatase and
osteocalcin, was also reported in ovariectomized rat models trea-
ted with resveratrol.(32) Resveratrol has also been shown in vitro
to impair osteoclast formation by inhibiting RANKL-induced
nuclear factor-kappa beta (NF-κB) signaling cascade during
osteoclastogenesis. Specifically, resveratrol has the capacity to
suppress IκB-alpha kinase phosphorylation and kinase activity
and degradation to p65 dimers. In further inhibiting the
RANKL-induced NF-κB osteoclastogenesis, NAD-dependent dea-
cetylase sirtuin-1 (SIRT-1) activity is upregulated by resveratrol,
which in turn deactivates P300 acetyltransferase (an enzyme that
promotes cell maturation and differentiation into specialized
function) and acetylation of NF-κB-p65.(33)
Besides estrogen-deficiency bone loss, senile osteoporosis also
occurs concurrently in the later stage of postmenopausal osteopo-
rosis in which pluripotent bone marrow mesenchymal stem cells
preferentially differentiate into adipocytes over osteoblasts. Just
10 mg of resveratrol per kilogram of body mass per day for
10 weeks attenuated trabecular and cortical bone loss in the femo-
ral neck of very old rats (22 months old).(34) The preservation of the
femur microarchitecture in a senile osteoporosis model is likely
attributable to resveratrol-induced enhancement of osteogenesis
and inhibition of adipogenesis in human mesenchymal stem cells,
primarilymediated through the SIRT-1 pathway, with a small contri-
bution from estrogenic signaling.(35) However, resveratrol appeared
to be detrimental to male rats in the early stage of aging after
administration of 20 mg of resveratrol per kilogram of body mass
per day for 12 weeks. The reduction in the trabecular bone volume
of the tibia was accompanied by a decline in osteocalcin expression
and an increase in resorption marker CTX, which was not offset by
the slight increase in SIRT-1 gene expression that mediates osteo-
calcin and alkaline phosphatase expressions.(36)
An important point to consider is the dose of resveratrol used to
alleviate a particular health condition. Although Isabel and col-
leagues found that a 10 mg/kg dose of resveratrol attenuated
senile osteoporosis,(34) a subsequent study by Lee and colleagues
found that the same dose exacerbated methotrexate-induced
reduction in growth plate thickness, trabecular bone volume, and
metaphyseal primary spongiosa height, and increased marrow adi-
posity in young rats. In contrast, they found that a 1 mg/kg dose
was sufficiently potent to negate the chemotherapy-induced oste-
oclastic activity, thereby enabling normal endochondral bone
growth and new bone deposition during treatment.(37) Indeed,
our dose–response studies have consistently shown that the maxi-
mal improvements in systemic and cerebral vasodilator function in
humans with hypertension or type 2 diabetes were achieved with
the lowest resveratrol dose used.(19,38) Taken together, the mecha-
nisms underlying the important bone-protective effect of resvera-
trol in elderly women may be via upregulating osteoprotegerin
expression to reduce bone resorption activity, and simultaneously
by inhibiting adipogenesis to favor osteoblast formation. Impor-
tantly, the optimal dose of resveratrol required to alleviate a partic-
ular health condition in a specific population should be determined
in a dose–response study preceding an intervention trial.
Resveratrol-induced improvement in vasodilator function is
another plausible bone-protective mechanism. Impaired blood
flow in the lower extremities is associated with decreased BMD
in the hip and ankle, independent of exogenous estrogen
use.(39) Administering eldecalcitol, a derivative of 25-dihydroxy
vitamin D3, in ovariectomized rats has resulted in an improve-
ment in vascular function and increased BMD of lumbar verte-
brae and femur.(40) The evidence for resveratrol improving
vascular function in humans is well established.(19,20,41) In our
recently published article reporting on the other outcomes of
the RESHAW trial, CVR improved by 12% relative to placebo.(22)
To the best of our knowledge, this is the first clinical study to
report a significant positive correlation between resveratrol-
induced improvements in microvascular function and femoral
neck T-score, supporting the importance of adequate perfusion
for bone homeostasis.
Additive benefit of resveratrol on bone health with
vitamin D and/or calcium supplementation
Consumption of vitamin D and/or calcium supplements for main-
taining bone health is widespread among the elderly population.
Hence, we undertook a subgroup analysis to identify potential syn-
ergies with resveratrol in participants who took vitamin D and/or
calcium supplements. The 12-month parallel comparison showed
that those who took calcium with or without vitamin D had a
greater increase in lumbar spine BMD than those who took neither.
Factorial analysis confirmed this observation. In the crossover com-
parison, those who took both calcium and vitamin D had a greater
resveratrol-induced increase in lumbar spine BMD than those tak-
ing calcium only. They also had a significantly greater increase in
total hip BMD and reduction in hip fracture risk than those taking
neither calcium nor vitamin D. We acknowledge that small sample
sizes in the vitamin D and/or calcium groups limit interpretation of
potential interactions. In addition, we did not collect data on the
participants’ serum 25-hydroxyvitamin D levels or monitor dietary
intake of calcium as the effect of resveratrol on bone health was a
secondary outcome of this study. Hence, how these variablesmight
have affected the responsiveness to resveratrol remains unknown.
However, it is worth noting that the 12-month duration of treat-
ment phases in the crossover study design allowed us to assess
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within-individual treatment effects on bone parameters without
confounding effects of seasonal variation in 25-dihydroxy vitamin
D3 status, thus increasing the reliability of the observed
resveratrol-induced changes in parameters of bone health.
Notwithstanding the small sample sizes, there appears to
be an additive benefit of resveratrol on BMD in women who
took both vitamin D and calcium supplements. It is well estab-
lished that vitamin D and calcium act synergistically to pro-
mote bone formation. Vitamin D assists bone formation by
activating collagen type 1α, osteocalcin, and alkaline phos-
phatase gene transcription(42) and, after conversion to
1,25-hydroxyvitamin D, vitamin D facilitates calcium absorp-
tion in the gut and helps maintain adequate calcium concen-
tration to promote bone mineralization. Meta-analyses
showed that supplementing with calcium plus vitamin D
could reduce the risk of total and hip fractures by 15% and
30%, respectively,(43) but vitamin D alone or calcium alone
failed to produce meaningful effects on BMD.(44,45) The addi-
tive benefits of resveratrol with vitamin D and calcium may
be attributable to the enhancement of vitamin D receptors
in bone cells stimulated by resveratrol.(46) As a phytoestrogen,
resveratrol has a similar structure to estrogen, which has been
shown to upregulate vitamin D receptors in osteoblast-like
cells to upregulate bone formation.(47) The presence of vita-
min D appears to amplify the biological effects of resveratrol.
Compared with resveratrol alone, the combination of vitamin D
plus resveratrol enhanced the intracellular concentration of res-
veratrol, increased activation of estrogen-receptor-β and vitamin
D receptor expression, and boosted the bioavailability of resvera-
trol and vitamin D, thereby increasing their ability to rapidly cross
the cell membrane and to reach target tissues.(48) Furthermore,
vitamin D also has a critical role in vascular function. Data from a
larger community-based study of older adults showed a signifi-
cant association between vitamin D status and endothelial vasodi-
latation; however, this was only evident in older women.(49) From
our data, the vitamin D only group showed a strong correlation
between the improvements in CVR and femoral neck T-score with
resveratrol, relative to other groups, suggesting that this unique
combinationmay potentially improve vascular function and bone
health synergistically. No clinical trials have been undertaken to
investigate the synergistic benefit of resveratrol with vitamin D
and/or with calcium on bone health. If our hypothesis is con-
firmed, it may offer a clinically meaningful and significant benefit
to counteract postmenopausal osteoporosis.
In conclusion, low-dose resveratrol supplementation signif-
icantly improved BMD of the lumbar spine and femoral neck
and reduced the bone resorption marker, CTX, in postmeno-
pausal women. The magnitude of benefit was greater for
women with suboptimal bone metabolism. The resveratrol-
induced improvement in CVR and femoral neck T-score sug-
gests that improvement of the microcirculation may be an
additional area to target in preventing postmenopausal oste-
oporosis. Furthermore, the benefits of resveratrol on spine
and hip BMD appeared to be amplified in women who regu-
larly consume vitamin D and calcium supplements. Additional
clinical randomized controlled trials are warranted to test
whether this unique combination can improve the vascular
and osseous profiles of the elderly women.
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